Show Notes
馃挰 Artificial intelligence and big data are flooding discovery pipelines with high-potential drug candidates, but this rapid innovation has triggered a crisis. Simply put, our capability to design miracle molecules is vastly outstripping our technology to mass-manufacture them safely for the global public. Moving drug making from the scale of lab flasks to commercial bioreactors introduces non-linear biological and engineering shifts that can undermine tasks like purification.
鈿n this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap between drug discovery and the pharmacy shelf.
Our guests are:
Henrik Ihre, Distinguished Fellow, Cytiva
Paul Belcher, Business Leader, Cytiva
馃帶 Stay tuned to learn about:
鉃� The process of taking a drug from theoretical to the shop shelf
鉃� How the drug purification works
鉃� The human cost when purification goes wrong
鉃� The challenges of keeping pace as AI supercharges drug discovery
Chapters:
(00:00) Intro – How drugs go from discovery to reality
(03:49) The purification process
(10:05) Why small scale success doesn’t mean industrial scale success
(13:00) The challenge of the expanding drug pipeline
(21:39) Understanding the molecules that are being purified
(23:20) What is a chromatography resin?
(25:24) Why purification gets more difficult later in the process
(27:15) The human impact when purification goes wrong
(32:59) The future of AI drug discovery
(37:52) Is AI helping with purification?
(40:32) How it feels to be advancing drug discovery
About the sponsor:
Cytiva:
About the podcast:
New Scientist CoLab explores the boundaries of innovation and the intersection of business, science and technology. Hosted by Justin Mullins.
Don’t miss an episode – subscribe now:
Connect with New Scientist:
Website: 鈦�/鈦�
Instagram:
Learn more about your ad choices. Visit